SINGULAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5565473 (Pediatric) | ORGANON | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
Aug, 2012
(11 years ago) | |
| US8007830 | ORGANON | Granule formation |
Oct, 2022
(1 year, 6 months ago) | |
Singulair is owned by Organon.
Singulair contains Montelukast Sodium.
Singulair has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Singulair are:
- US5565473*PED
- US8007830
Singulair was authorised for market use on 20 February, 1998.
Singulair is available in tablet;oral, granule;oral, tablet, chewable;oral dosage forms.
The generics of Singulair are possible to be released after 24 October, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 26, 2015 |
Drugs and Companies using
MONTELUKAST SODIUM ingredient
Market Authorisation Date:
20 February, 1998Treatment:
NADosage:
TABLET;ORAL; TABLET, CHEWABLE;ORAL; GRANULE;ORAL
How can I launch a generic of SINGULAIR before its drug patent expiration?
More Information on Dosage
SINGULAIR family patents
